Revolve Gr에 대한 매도 수량은 투자자에게 Revolve Gr의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Revolve Gr (NYSE:RVLV) 주식, 공매도 수량 보고

REVOLVE GROUP INC

Revolve Gr

Revolve Group Inc is an emerging e-commerce retailer, selling women's dresses, handbags, shoes, beauty products, and incidentals across its marketplace properties, Revolve and FWRD. The platform is built to suit the "next-generation customer," emphasizing mobile commerce, influencer marketing, and occupying an aspirational but attainable luxury niche. With $1.1 billion in 2024 net sales, the firm sits just outside the top 30 apparel retailers (by sales) in the U.S, but has consistently generated robust top-line growth as the industry continues to favor digital channels. Revolve generates approximately 18% of sales from private-label offerings, while focusing on building an inventory of distinctive products from emerging fashion brands with less than $10 million in annual sales.

Revolve Group Inc

Trading Ideas

HCHL

Happy City Holdings Shares Halted On Circuit Breaker To The Downside At $6.08/Share

News

IPOs

Happy City Holdings Shares Open For Trade at $6.75/Share

As part of its efforts to turbocharge retail trading strategies, Defiance ETFs has launched three new <a href="https://www.benzinga.com/etfs">single-stock ETFs</a> offering daily leveraged and inverse exposure to some of the most talked-about tech stocks: IonQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>), Oklo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>), and SoundHound AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>). 
These funds come days after Defiance launched the Daily Target 2x Short PLTR ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTZ#NASDAQ">PLTZ</a>), the first leveraged inverse fund to focus on Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>). This fund provides short sellers with a new means to double down, literally, on short-term dips in the contentious software company. The new set includes: Defiance Daily Target 2X Short IONQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONZ#NASDAQ">IONZ</a>) – a fund aiming for a negative 200% of the day&#8217;s action in quantum computing firm IonQ Inc., designed for traders with short-term bearish views on the stock.
Defiance Daily Target 2X Long OKLO ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKLL#NASDAQ">OKLL</a>) – offering 200% daily exposure to Oklo, a nuclear fission and fuel recycling specialist; Defiance Daily Target 2X Long SOUN ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUX#NASDAQ">SOUX</a>) seeks 200% of the daily moves in SoundHound AI, a firm known for its voice AI tech used in cars and connected devices. In contrast to conventional margin-based trading, these ETFs provide investors with leveraged exposure in an ETF wrapper, allowing retail traders to take action on firm beliefs without a margin account or options trading eligibility.
Each fund is constructed for short-term tactical trading, where daily compounding is the game. These are not buy-and-hold vehicles. Holding them longer than one day without active management can create unintended consequences, particularly in volatile markets.
By zeroing in on innovative businesses in emerging fields relevant to these times, from quantum computing and nuclear technology to conversational AI, Defiance is doubling down on the &#8220;high risk, high reward&#8221; set. But with more power comes more volatility. These instruments can zip quickly and violently, so though they might seem like trader candy, they&#8217;re wisely managed with a disciplined approach.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/06/46060843/vanguard-etfs-lead-2025-with-150-billion-inflows-challenging-wall-streets-old-guard">Vanguard ETFs Lead 2025 With $150 Billion Inflows, Challenging Wall Street&#8217;s Old Guard</a></li>
</ul>
Photo: Shutterstock

New ETFs

ETFs

IONQ

IONZ

OKLL

OKLO

PLTR

PLTZ

SOUN

SOUX

New Defiance ETFs Offer 2X Bull And Bear Exposure To IonQ, Oklo And SoundHound AI

<a href="https://www.youtube.com/watch?v=iQAnZXa1Kpg">https://www.youtube.com/watch?v=iQAnZXa1Kpg</a>
&nbsp;

Macro Economic Events

Economics

Federal Reserve

Fed Chair Powell Says Banks Are Free To Provide Banking Services To Crypto Industry, Conduct Activities As Long As Protect Safety And Soundness

Rumors

Happy City Holdings IPO Indicating $6.10/Share On 94K Shares; IPO Priced At $5/Share On 1.1M Shares

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) has reportedly <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">launched its weight-loss</a> drug Wegovy (semaglutide) in India to compete with Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
In March this year, U.S. pharma giant Eli Lilly launched its popular weight loss drug Mounjaro (tirzepatide) in India. It is expected to have the second-largest population of overweight or <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">obese people by 2050</a>.
A Reuters report on Tuesday said that Wegovy, a weekly injection, will be available in pharmacies by the end of this month. It could take some market share away from Eli Lilly. Meanwhile, sales of Eli Lilly's drug Mounjaro rose 60% between April and May, the report highlighted, citing industry analysts.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/46050655/novo-nordisks-weight-loss-injection-cagrisema-data-sparks-investors-concern" rel="noreferrer noopener">Novo Nordisk&#8217;s Weight Loss Injection CagriSema Data Sparks Investor Concern</a>
Novo Nordisk told Reuters that Wegovy is available in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg doses. The first three will be priced at 4,336 rupees ($50.7), and the monthly cost will be 17,345 rupees ($201.4), similar to Eli Lilly&#8217;s Mounjaro.
The Reuters report added that Wegovy&#8217;s 1.7 mg dose will be priced at 24,280 rupees ($281.90) and 2.4 mg at 26,015 rupees.
Mounjaro, a once-weekly injection approved by India's drug regulator, is priced at 4,375 Indian rupees ($50.86) for a 5 mg vial and 3,500 rupees for a 2.5 mg vial, its lowest dose, the company told Reuters. Its highest dose is 15 mg.
On Monday, Novo Nordisk announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for updating the Ozempic (once-weekly semaglutide) label to reflect the positive data from the STRIDE peripheral artery disease (PAD) functional outcomes trial.
Following the <a target="_blank" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916358" rel="noreferrer noopener">positive</a> opinion from the CHMP, Novo Nordisk expects the European Commission to implement the label update within approximately two months.
Novo Nordisk has also filed for a label expansion of Ozempic in the U.S., and a decision is expected in the last quarter of 2025.
Based on data from the SOUL trial, Novo Nordisk has also filed with the EMA and FDA for a label expansion for Rybelsus.
This could potentially make Rybelsus the first and only oral GLP-1 RA with proven cardiovascular (CV) benefits. A decision is also expected in the second half of 2025.
On Monday, the New England Journal of Medicine (NEJM) published results from Novo Nordisk&#8217;s phase 3 REDEFINE 1 trial of CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a weight-related medical <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/46050655/novo-nordisks-weight-loss-injection-cagrisema-data-sparks-investors-concern" rel="noreferrer noopener">complication and without diabetes</a>.
Price Action: NVO stock is up 1.25% at $70.59 at last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46067629/hims-ceo-slams-novo-nordisk-for-anticompetitive-demands-after-ozempic-maker-abruptly-ends-partnership-we-refuse-to-be-strong-armed" target="_blank" rel="noreferrer noopener">Hims CEO Slams Novo Nordisk For &#8216;Anticompetitive Demands&#8217; After Ozempic Maker Abruptly Ends Partnership: &#8216;We Refuse To Be Strong-Armed&#8217;</a></li>
</ul>
Photo by Tobias Arhelger via Shutterstock

Biotech

Large Cap

Health Care

General

Novo's India Move Could Reshape The Weight-Loss Drug War With Eli Lilly

Hoth Therapeutics' HT-001 Achieves 100% Response Rate&nbsp;in at least one endpoint&nbsp;in Phase 2a Trial in PK Patients for EGFR Inhibitor-Related Skin Toxicities.
Hoth Therapeutics will host a Key Opinion Leader (KOL) event on, at&nbsp;3:30PM EST&nbsp;to highlight recent clinical progress with HT-001, a novel topical therapeutic developed to address EGFR inhibitor-induced skin toxicities in cancer patients. This event will feature insights from derm-oncology and dermatology specialists&nbsp;Jonathan Hale Zippin M.D.,&nbsp;Ph.D., and&nbsp;Adam Friedman M.D., F.A.A.D., who will present interim results from the ongoing Phase 2 trial and discuss how HT-001 could redefine supportive care standards for oncology patients.&nbsp; Access/join the event through the following link:&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4455869-1&amp;h=3734374131&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4454206-1%26h%3D3911180385%26u%3Dhttps%253A%252F%252Fzoom.us%252Fj%252F91353016981%26a%3Dhttps%253A%252F%252Fzoom.us%252Fj%252F91353016981&amp;a=https%3A%2F%2Fzoom.us%2Fj%2F91353016981">https://zoom.us/j/91353016981</a>.
Phase 2a Trial Highlights (CLEER-001)
<ul>
<li>100% of enrolled patients in open-label cohort achieved at least one primary endpoint of clinical dermatologic improvement</li>
<li>Over 65% reported reductions in pain and pruritus (itching)</li>
<li>0% required dose reduction or discontinuation of their EGFRI therapy.</li>
<li>Topical therapy was well tolerated with no serious adverse events.</li>
</ul>
NEW YORK, June 24, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOTH#NASDAQ">HOTH</a>), a clinical-stage biopharmaceutical company developing targeted therapies for rare and serious inflammatory conditions, today announced that its investigational candidate HT-001 met the primary efficacy endpoint&nbsp;in at least one metric&nbsp;in 100% of patients in its ongoing Phase 2a clinical study (CLEER-001) evaluating treatment for epidermal growth factor receptor inhibitor (EGFRI)-induced cutaneous toxicities.
EGFR inhibitors, used widely to treat non-small cell lung cancer (NSCLC), pancreatic, breast, colorectal, and head and neck cancers, are associated with dermatologic side effects in up to 90% of patients, often resulting in painful rashes, pruritus, dryness, nail changes, and alopecia. These adverse events frequently force dose reductions or treatment discontinuation, limiting therapeutic efficacy and patient outcomes.

HOTH

Hoth Therapeutics' HT-001 Achieves 100% Response In Phase 2a Trial For EGFR Inhibitor-Related Skin Toxicities

<a href="https://www.youtube.com/watch?v=iQAnZXa1Kpg">https://www.youtube.com/watch?v=iQAnZXa1Kpg</a>

Macro Notification

Politics

Fed Chair Powell Says In Housing, There's A Longer-Run Shortage That Fed Cannot Affect; Says Absolute Best Thing We Can Do For Housing Is To Restore Price Stability

SLNO

Watching Soleno Therapeutics; Shares Move Higher, M&A Blog Suggests The Co Has Received Takeover Approaches

Trading Halt: Halt status updated at 10:35:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

Fed Chair Powell Says Reason We Are Not Cutting Rates Is That Forecasts In And Out Of Fed Expect Meaningful Increase In Inflation This Year

A growing number <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46060293/whale-who-netted-1-23-million-from-ethereum-long-now-flips-bearish-with-high-leverage-bitcoin-short">of affluent investors</a> are turning to financial advisors for digital asset guidance, but many are skeptical about whether their advisors have sufficient crypto expertise, according to a new study by CoinShares.
The survey, which <a href="https://coinshares.com/en/d/insights/survey/us-investors-survey-06-2025/">polled</a> 500 wealthy U.S. investors, reveals a clear appetite for digital assets across wealth tiers, but also a persistent credibility gap.
While 82% of respondents said they would be more inclined to work with a financial advisor who offers crypto-related investment advice, nearly a third flagged major concerns about the depth of advisors' personal experience and risk transparency when it comes to digital assets.
"Investors aren't just asking, ‘What should I buy?' They're asking, ‘Do you understand this space as well as I do?'" said Jean-Marie Mognetti, CEO of CoinShares. 
"There is a significant opportunity for advisors who invest in their own credibility to differentiate themselves in this competitive market."
The report indicates that digital assets are no longer a fringe interest. 
Nearly nine in ten digital asset holders surveyed said they plan to increase their crypto exposure in 2025, and more than half of these investors monitor or trade digital assets at least daily. 
Notably, even among those without current crypto exposure, 75% expressed interest in learning more or planning to invest in the near future in cryptocurrencies like Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>).
Despite their enthusiasm, many investors remain cautious. 
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46071825/big-short-investor-eisman-warns-jpmorgan-wells-fargo-domination-squeezes-regional-banks">&#8216;Big Short&#8217; Investor Eisman Warns JPMorgan, Wells Fargo Domination Squeezes Regional Banks</a>
The survey found that potential security risks (54%), regulatory uncertainty (52%) and market volatility (51%) were the top concerns when considering digital asset investments.
Investors also worry about crypto's speculative nature, scams, and a lack of accessible, reliable information.
While most investors are self-directed, 45% said they are very comfortable making crypto investment decisions independently, the majority still view financial advisors as trusted partners. 
CoinShares found that 88% of current digital asset investors already work with a financial advisor, and 78% of non-crypto investors would consider working with an advisor if they provided digital asset guidance.
However, investors are looking for more than surface-level support. 
They expect advisors to offer comprehensive services, including access to secure and compliant investment vehicles (54%), portfolio risk management strategies (54%), and custody and security best practices (51%). 
Many also value tax and regulatory guidance, due diligence on specific crypto projects, and education on emerging opportunities like decentralized finance (DeFi) and tokenization.
The study also highlighted the biggest red flags investors see when working with advisors on crypto. 
The most frequently cited concerns included advisors lacking personal experience with digital assets (29%) and recommending crypto products without fully explaining the associated risks (29%). 
Another 22% pointed to advisors holding outdated views on crypto markets.
Mognetti emphasized that trust in crypto is built on more than product access, it requires advisors to be fully engaged and credible in the space. 
"Digital asset adoption is advancing rapidly among investors who are self-educated and actively involved—but that doesn't mean they want to go it alone. They're looking for advisors who can serve as strategic partners, not just product providers,&#8221; he said.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46071615/d3-global-launches-1m-developer-fund-to-advance-tokenized-domains-on-doma-testnet">D3 Global Launches $1M Developer Fund To Advance Tokenized Domains On Doma Testnet</a></li>
</ul>
Image: Shutterstock

$BTC

Wealthy Investors Want Crypto Advice But Doubt Their Advisors' Experience: Report

American investor and entrepreneur, Anthony Pompliano, today announced that ProCap BTC, LLC, a bitcoin-native financial services firm (the "Company"), has purchased 3,724 bitcoin at a time weighted average price ("TWAP") of $103,785 per bitcoin, following the Company's June 23, 2025 announcement of a proposed $1 billion business combination with&nbsp;Columbus Circle Capital Corp. I (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCCM#NASDAQ">CCCM</a>) to take the Company public as ProCap Financial, Inc. The Company now holds 3,724 bitcoin on its balance sheet.
The bitcoin was acquired as part of the Company's on-going bitcoin purchase program. The Company has wasted no time delivering for its investors by deploying the funds raised at signing to accumulate bitcoin. As a result, equity investors received immediate bitcoin exposure from the equity raise.
The Company plans to continue buying bitcoin for its balance sheet as part of its ongoing business strategy. At the closing of the proposed business combination, ProCap Financial is expected to hold up to $1 billion in bitcoin on its balance sheet.&nbsp;The TWAP for the Day 1 purchases may be different from the "Signing Bitcoin Price" for purposes of Business Combination Agreement signed by CCCM and the Company on June 23, 2025.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

CCCM

ProCap BTC Buys 3,724 Bitcoin At An Average Price Of $103,785 Following $1B SPAC Deal Announcement, Plans To Hold Up To $1B In Bitcoin Post-Merger

RBC Capital analyst Nik Modi reiterates PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) with a Sector Perform and maintains $148 price target.

Price Target

Reiteration

Analyst Ratings

RBC Capital Reiterates Sector Perform on PepsiCo, Maintains $148 Price Target

Expeditious Transition Enables Airline to Deploy Aircraft to Maximize Peak Summer Travel Season
CDB Aviation, a wholly owned Irish subsidiary of China Development Bank Financial Leasing Co., Limited ("CDB Leasing"), announced today the delivery of three Airbus A320neo aircraft to its long-standing customer, Controladora Vuela Compañía de Aviación, S.A.B. de C.V. ("Volaris").

VLRS

CDB Aviation Delivers Three Airbus A320neo Aircraft To Volaris

Fed Chair Powell Says Story Has Been Evolving, Our Thinking Has Been Adapting; Too Early To Know Economic Implications Of Middle East; We Are Not Facing A Tension Between Mandates

Fed Chair Powell Says Fed Projections Are For Inflation To Move Up Because Of Tariffs; What Will Happen With Rates Will Depend On Economy; Significant Majority Of Policymakers Feels Will Be Appropriate To Reduce Rates Later This Year; Projections Subject To Great Uncertainty

<a href="https://www.clevelandfed.org/collections/speeches/2025/sp-20250624-fourth-district-groundhog-in-londons-financial-district" title="https://www.clevelandfed.org/collections/speeches/2025/sp-20250624-fourth-district-groundhog-in-londons-financial-district">https://www.clevelandfed.org/collections/speeches/2025/sp-20250624-fourth-district-groundhog-in-londons-financial-district</a>

Fed's Hammack Says Labor Market Seems Stable, Immigration Restrictions Could Be Barrier To Growth In Medium Term

Shares of Royal Caribbean Cruises Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) are surging Tuesday morning, trading in sympathy with competitor Carnival Corp after the company announced blockbuster financial results for the second quarter.
What To Know: Tuesday&#8217;s rally was ignited by Carnival&#8217;s <a href="https://www.benzinga.com/pressreleases/25/06/n46073683/carnival-corporation-plc-tops-guidance-achieving-highest-ever-second-quarter-operating-results-and">strong performance</a>, which included record second-quarter revenues of $6.3 billion. The company reported adjusted net income of $470 million, outperforming its previous guidance by $185 million. 
This was driven by what CEO Josh Weinstein described as &#8220;a phenomenal quarter&#8221; with strong close-in demand and onboard spending. Further demonstrating robust consumer interest, Carnival's customer deposits reached an all-time high of $8.5 billion.
Carnival's <a href="https://www.benzinga.com/pressreleases/25/06/n46073683/carnival-corporation-plc-tops-guidance-achieving-highest-ever-second-quarter-operating-results-and">outlook</a> also fueled investor optimism. The company raised its full-year 2025 guidance, now expecting adjusted net income to be $200 million higher than previously forecasted and projecting a full-year adjusted EBITDA of approximately $6.9 billion.
The overwhelmingly positive data from Carnival is leading investors to bet on the entire sector&#8217;s health Tuesday morning. The record revenues, deposits and profitability reported by Carnival suggest powerful tailwinds, including high demand and strong pricing, are lifting all major cruise lines.
Price Action: RCL shares are trading higher by 2.8% to $281.39 Tuesday morning. According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, RCL has a 52-week high of $285.50 and a 52-week low of $130.08.
Read Also: <a href="https://www.benzinga.com/general/travel/25/05/45680686/premium-travel-demand-gives-airlines-hotels-and-cruises-an-edge-in-2025-goldman-sachs">Premium Travel Demand Gives Airlines, Hotels And Cruises An Edge in 2025: Goldman Sachs</a>
<h2 class="wp-block-heading">How To Buy RCL Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Royal Caribbean&#8217;s case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Image: Shutterstock

What's Going On With Royal Caribbean Cruises (RCL) Stock?

RBC Capital analyst Brian Abrahams maintains Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Outperform and raises the price target from $35 to $75.

CDTX

RBC Capital Maintains Outperform on Cidara Therapeutics, Raises Price Target to $75

Press Releases

Revolve Group, Inc. to Announce Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Revolve Group, Inc. to Present at Upcoming Morgan Stanley and UBS Investor Conferences

REVOLVE GROUP ANNOUNCES PERMANENT STORE AT THE GROVE IN LOS ANGELES

Earnings

Revolve Group Announces Fourth Quarter and Full Year 2024 Financial Results

REVOLVE x BELLEMINT Announce Worldwide Launch, Bringing Fashion and Gaming Together Like Never Before

Entertainment

REVOLVE RETURNS TO THE DESERT FOR THE 8TH ANNUAL REVOLVE FESTIVAL

REVOLVE PRESENTS THE 8TH ANNUAL REVOLVE FESTIVAL

Revolve Group, Inc. to Announce First Quarter 2025 Financial Results on May 6, 2025

Revolve Group Announces First Quarter 2025 Financial Results

Revolve Group, Inc. to Present at Upcoming Baird, TD Cowen and William Blair Investor Conferences

RVLV

American Eagle Outfitters, Inc. Common Stock

American Eagle Outfitters

a.k.a. Brands Holding

Abercrombie & Fitch

Buckle

Boot Barn Holdings

Burlington Stores

Caleres

Citi Trends

Torrid Holdings

Foot Locker

Genesco

Guess

J.Jill

Lands' End

LuxExperience B.V. American Depositary Shares, each representing one Ordinary Share

Comments

Revolve Gr

매도 수량

Revolve Gr (NYSE:RVLV) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌